title: Perspectives on lymphangiogenesis and angiogenesis in cancer.
abstract: Tumor-associated neovascularization allows tumor cells to express their critical growth advantage, whereas lymphatic invasion is crucial for the metastatic process. Various growth factors stimulate blood and lymphatic neovascularization and modulate vessel permeability in tumors. The first anti-angiogenic drugs are already in routine use, and new anti-vascular therapeutics are evaluated in clinical trials. Conversely, pro-lymphangiogenic therapy could be implemented to treat cancer survivors suffering from secondary lymphedema.
authors.affiliation: Molecular/Cancer Biology Laboratory, Research Program Unit, Department of Pathology, Haartman Institute, Institute for Molecular Medicine Finland, Helsinki University Central Hospital, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.
authors.forename: Tanja
authors.initials: T
authors.lastname: Holopainen
authors.forename: Maija
authors.initials: M
authors.lastname: Bry
authors.forename: Kari
authors.initials: K
authors.lastname: Alitalo
authors.forename: Anne
authors.initials: A
authors.lastname: Saaristo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D006801:Humans; D042583:Lymphangiogenesis; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000503:physiopathology* / Q000517:prevention & control; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A